Introduction
Infective endocarditis (IE) is associated with a high in-hospital mortality around 20%. [1] [2] [3] [4] European and American guidelines agree to consider patients with prior IE, a prosthetic heart valve, or cyanotic congenital heart disease (CHD) at high risk of developing IE and recommend special attention for these patient groups (e.g. antibiotic prophylaxis in relation to dental procedures). 5, 6 High-risk patients have been found to have a 100-fold increase in the incidence rate compared with the background population, in whom IE incidence rate has been estimated to be 4-7.5/100 000 person-years (PY). [7] [8] [9] [10] However, the studies investigating the incidence rates among high-risk patients have been conducted almost 25 years ago and contemporary data are therefore needed. [7] [8] [9] [10] Further, these studies were carried out on selected study populations and nationwide data could contribute with an unselected real-life study population. Thus, examination of the incidence of IE in high-risk patients may increase clinical attention in these patients. Further, it is needed to compare the incidence of IE in the high-risk population with the general population to quantify the potential benefit of antibiotic prophylaxis for these high-risk patients. To address this issue, we examined the incidence of IE among high-risk patients in a nationwide population. Using Danish nationwide registries, we were able to study a large cohort with long-term follow-up.
Methods

Data sources
In Denmark, every citizen is provided with a unique personal number, making it possible to identify every Danish citizen in different nationwide administrative registries. We used the National Population Registry, the National Patient Registry, and the Danish Prescription Registry. The National Population Registry holds information on gender, date of birth, and date of death on all Danish citizens. 11, 12 Through the registries, we assessed the patients' co-morbidity and concomitant pharmacotherapy. Claimed prescriptions 6 months prior to index date were obtained to study baseline medication.
Study population
We identified all patients who (i) were diagnosed with first-time IE (ii) underwent heart valve surgery (see Supplementary material online, Table S1 for specific procedure codes), or (iii) were diagnosed with certain complex CHD (see Supplementary material online, Table S1 ) in the period from 1 January 1996 to 31December 2015. A flow chart of the patient selection is illustrated in Figure 1 . Infective endocarditis was defined by ICD-8 or ICD-10 codes (421, I33.X, I38.X, and I39.8). The IE diagnoses have been validated in the National Patient Registry in a previously published study reviewing a total of 2153 medical records. 13 The authors found a positive predictive value of the IE diagnoses of 0.82. 13 However, to improve the likelihood of the diagnosis, patients with an IE diagnosis who were not admitted to hospital or who had a hospitalization length of stay <14 days were not counted as having IE. Patients who died in-hospital with an IE diagnosis and a hospitalization <14 days were counted as having IE.
Guidelines from the American Heart Association (AHA) and the European Society of Cardiology (ESC) consider patients with prior IE, a prosthetic heart valve, and cyanotic CHD patients at high risk of IE. Cyanotic CHD patients are difficult to assess through administrative registries since no clinical data are available. Therefore, we identified patients with three complex CHD, which were identified by the ICD-8 (before 1994) and ICD-10 (1994-present) classification system from the National Patient Registry (see Supplementary material online, Table S1 ).
The following diagnoses were used to identify patients with one of the selected complex CHDs: truncus arteriosus (Q20.0), transposition of great arteries (Q20.3), and tetralogy of Fallot (Q21.3) as done previously. 14 These diagnoses have been validated with a positive predictive value of 0.56 for DQ20.0 and 0.9 for both DQ20.3 and DQ21. 3. 15,16 These patients are in Danish clinical practice considered at high risk of IE even after surgical correction.
Some patients could overlap between groups. Patients who underwent heart valve surgery during IE hospitalization were subcategorized for further analysis but was included in the prior IE group (Figure 1) and not in the heart valve group. Patients diagnosed with a complex CHD after implantation of a prosthetic heart valve or after hospitalization due to IE were categorized as patients with a prosthetic heart valve or as patients with prior IE.
For each study group (prior IE, prosthetic valve, and complex CHD), patients were matched by gender and age with controls from the background population with four controls for every case. A difference of maximum 2 years of age was accepted when the study groups were matched by age. For the purposes of sensitivity, patients who underwent heart valve surgery during first-time IE admission were also compared with the controls from the background population. The greedy match algorithm was used for matching. 17 
Follow-up and outcome
Patients were considered at high risk of IE from 90 days after hospital discharge (90 days grace period) from IE diagnosis, heart valve surgery, or complex CHD diagnosis, whichever came first (index date). The index date of 90 days after hospital discharge was chosen to ensure that this new admission was in fact a new event and not a continuation of the prior admission. For the complex CHD patients that are followed in long-term ambulatory courses, we used the first hospital admission for a complex CHD as the index date. Patients were followed until the end of study period (31 December 2015), death, emigration, hospitalization due to IE, or a maximum of 10 years of follow-up, whichever came first.
Statistics
Patient characteristics were compared by study groups. Categorical variables were presented in counts and percentages, whereas continuous variables were presented with a median and 25 and 75 percentiles. Crude IE incidence rates were calculated by study groups and were presented per 1000 PY. Cumulative incidence plots were drawn for the time to IE by study groups and controls accounting for death as a competing risk using the cumulative incidence function. Gray's test was performed for the analysis of difference between curves. Further, a Kaplan-Meier plot illustrating survival probability according to the study groups was drawn, and the log-rank test was used to test for differences between curves.
Using multivariable adjusted Cox proportional hazard analysis, we compared the hazard rates of being hospitalized due to IE for each of the three risk groups with matched controls (one case for every four controls) from the background population. We adjusted for the following baseline characteristics: renal disease, pacemaker, aortic stenosis, rheumatic disease, and calendar year. The proportional hazard assumption was tested, and when not fulfilled, follow-up time was changed accordingly. The effect modification of age and gender was tested and linearity of continuous variables were tested.
For the purposes of sensitivity, analyses of IE incidence were carried out with a grace period from discharge (prior IE, prosthetic valve implantation, or complex CHD) of 0 and 182 days if the patient was discharged alive. Further, for complex CHD-patients, sensitivity analyses were carried out where risk date was set at birth.
Results were presented as hazard ratios (HR) with a 95% confidence interval (CI). A P-value <0.05 was considered statistical significant. All statistical analyses were performed using the SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA). The patient selection for the three study groups with the first diagnosis in the period from January 1996 to December 2015. *785 patients were stratified as patients with a prosthetic valve; 27 patients were stratified with a complex congenital heart disease. **1852 patients were stratified as patients with infective endocarditis; 185 patients were stratified with a complex congenital heart disease. ***Four patients were stratified as patients with infective endocarditis; 2 patients were stratified as patients with a prosthetic valve. ****During the endocarditis hospital stay. FU, follow-up. 
Results
As shown by Figure 1 , a total of 25 945 patients were included in the study: 5 096 patients with first-time IE, 19 478 patients who had undergone heart valve surgery, and 1371 with a complex CHD (54.2% tetralogy of Fallot, 37.3% transposition of great arteries, and 8.5% truncus arteriosus). Table 1 presents the baseline characteristics for the three corresponding study groups and the three control groups. Of the patients with prior IE, 1200 (23.5%) patients had heart valve surgery at their primary IE admission, as presented in Figure 1 .
Of the patients with complex CHD, 486 (35.5%) patients had heart surgery before index and 526 (38.4%) patients had heart valve surgery during follow-up. The number of incident high-risk patients increased during the study period from 567 patients in 1996 to 1931 patients in 2015. This increment was mainly driven by an increase in the number of patients with a prosthetic heart valve.
Incidence of infective endocarditis
The incidence of IE was 16.1/1000 PY [95% confidence interval (CI) 14.6-17.8/1000 PY] among patients with prior IE (including patients who had valve surgery during the first IE hospitalization), 6 .0/1000 PY (95% CI 5.5-6.5/1000 PY) among patients who with a prosthetic heart valve, and 1.5/1000 PY (95% CI 0.9-2.4/1000 PY) among patients with a complex CHD. Figure 2 presents the cumulative incidence of IE and mortality rate for the three study groups and the matched controls. The cumulative risk of IE for patients with prior IE was 7.3% and 8.8% at 5 and 10 years, respectively. For patients with a prosthetic valve, the cumulative risk of IE was 2.8% and 4.5% at 5 and 10 years, respectively, and for patients with a complex CHD, the cumulative risk was 0.9% and 1.3%, at 5 and 10 years, respectively. Subanalyses of patients who underwent valve surgery during hospital admission for first-time IE had an incidence of 13.3/1000 PY (95% CI 10.7-16.4/1000 PY); 6.7% and 8.7% had IE at 5 and 10 years, respectively.
Comparison with background population
Patients with prior IE were associated with a significant increased risk of IE compared with background population [hazard ratio (HR) 65.4, 95% CI 43.1-99.1; Figure 3 ]. Differences were seen in the magnitude of the association during follow-up but not in the direction (P < 0.0001 for interaction with time). Supplementary material online, Figure S1 shows a landmark analysis where follow-up time was varied into 0-6 months, 6-42 months, 42-84 months, and >84 months. For patients with a prior IE, age modified the associated risk of subsequent IE compared with the matched controls (P = 0.014) with an HR of 179.3 (95% CI 66.3-485.3) for patients aged >60 years and an HR of 43.0 (95% CI 27.0-68.5) for patients aged <60 years. Gender was not an effect modifier. Patients with a prosthetic valve were associated with a significant increased risk of IE compared with the matched controls (HR 19.1, 95% CI 15.0-24.4), as shown in Figure 3 . For prosthetic valve patients, differences were found in the 
magnitude of the association during follow-up but not in the direction (P = 0.008 for interaction with time). Age and gender were not effect modifiers for patients with a prosthetic heart valve.
For the complex CHD patients, no events occurred in the control group and therefore a HR could not be calculated.
Sensitivity analysis
We examined the incidence of IE with an index date set at 0 and 182 days after discharge. With no grace period, the incidence was 26.4/1000 PY (95% CI 24.4-28.5/1000 PY), 6.7/1000 PY (95% CI 6.3-7.2/1000 PY), and 1.5/1000 PY (95% CI 0.9-2.5/1000 PY) for patients with prior IE, prosthetic heart valve, and complex CHD, respectively. With a grace period of 182 days, the incidence was 13.7/1000 PY (95% CI 12.2-15.3/1000 PY), 5.7/1000 PY (95% CI 5.3-6.2/1000 PY), and 1.4/1000 PY (95% CI: 0.8-2.3/1000 PY) for patients with prior IE, a prosthetic heart valve, and a complex CHD, respectively. For comparison with background population, the overall results did not change. When risk date was changed to start at birth for complex CHD patients we identified an incidence of 0.9/1000 PY (95% CI: 0.5-1.7). Supplementary material online, Figure S2 shows the cumulative incidence of IE with the risk date set at birth and at time of diagnosis for complex CHD patients.
Discussion
This study examined the incidence of IE in patients at high risk (prior IE, prosthetic heart valve, and complex CHD). Our study yielded two major findings; first, the cumulative risks of IE at 10 years were 8.8%, 4.5%, and 1.3% for the patients with prior IE, prosthetic valve, and complex CHD, respectively and second, when compared with the matched controls from the background population, all three groups were associated with a substantial higher risk of IE.
Other observational studies have examined the incidence of IE. In the background population, studies have found an incidence of IE around 6.0/100 000 PY; 9, 10, 18, 19 however, in patients at highest risk (prior IE, prosthetic valve, cyanotic CHD), the incidence have been shown to be significantly higher. For patients with a prior IE, a review reported an IE incidence of 7.4/1000 PY. 7 Our results report a higher incidence in this patient group (16.1/1000 PY). Among patients with a prosthetic valve, a review reported an incidence of IE at 3.1-3.8/1000 PY, 7 where our study yielded an estimate of 6.0/1000 PY. These differences may be due to different use of the IE diagnosis in the administrative registries; however, our study is based on nationwide data, where the IE diagnosis has been validated with a positive predictive value of 0.82. 13 To the knowledge of the authors, this is the first study where the incidence of IE is reported for the patient groups constituting the IE high-risk population from the same database and on a national scale with complete data. Other cardiac predispositions have been found to increase the risk of IE. A case-control study found that case patients more often had a history of heart valve surgery, which is in line with our results. 20 The increasing age in the general population is anticipated to lead to an increment in the prevalence of patients with valvular heart disease, thus surgical and transcatheter treatment methods will be more widely used at a cost of a high risk of IE. Studies have shown that tetralogy of Fallot and transposition of the great arteries are the CHD diagnoses with the highest incidences of IE. [21] [22] [23] Our results showed an incidence of IE at 1.5/1000 PY in patients with truncus arteriosus, transposition of the great arteries, or tetralogy of Fallot in a large sample size with longterm follow-up. These data provide ranges of the incidence of IE in a high-risk population which is of use in the monitoring of patient care. However, translation into clinical work may be difficult because of the fact that these diseases represent a broad spectrum of pathology.
Comparison between groups are difficult to extrapolate to a clinical setting, however, the results stand as a benchmark for future studies in the monitoring of patient care and clinical interventions. Antibiotic prophylaxis has been recommended for this high-risk group even after the AHA and the ESC guidelines in 2007 and 2009 restricted the use of antibiotics for IE prophylaxis. 6, 24 In Denmark, antibiotic prophylaxis have been recommended for high-risk patients without any restrictions in this period. Our study shows that patients with prior IE, a prosthetic valve, and complex CHD have a substantial higher associated risk of IE compared with background population. In consideration of the low number of patients in these groups (however increasing), the use of antibiotics may be reasonable to prevent IE. 
Limitations
Our study has several limitations. The incidences of IE in our study may be underestimated since autopsies were not available; however, the incidences may also have been overestimated, given the high diagnostic suspicion of IE in patients with prior IE, a prosthetic valve, or complex CHD. Patients with complex CHD may suffer from other syndromes that may complicate the diagnosis for these patients. This may underestimate the true incidence of IE in patients with complex CHD. However, we believe that the results of this study represent a realistic incidence since the Danish administrative registries have been well validated in general for the diagnoses examined. 13, 16 However, the positive predictive value of the diagnosis, truncus arteriosus has been found to be 0.56 (95% CI 0.41-0.71); however, this patient group only constitute 8.5% of the complex CHD group included in our study. 16 Our data do not hold information on the microbiological aetiology, which limits our study.
The data used for this study are based on administrative registries using the ICD-10 diagnostic coding system, procedural codes, and prescription data from pharmacies. The registries were not able to differentiate between left-or right-sided IE and prosthetic valve endocarditis. AHA and ESC guidelines categorize patients with prior IE, a prosthetic heart valve, and cyanotic CHD as patients at high risk of IE. We identified patients with a complex CHD, however, we had no clinical information and we were not able to clarify whether the patients were cyanotic. Furthermore, the registries do not have information on in-hospital antibiotic treatment or microbiological aetiology. These data could have helped characterize the study population more extensively. We applied 90 days grace period to ensure that the IE was a relapse rather than a recurrent event. However, the lack of microbiological data limits our study in differentiating the re-IE as a relapse or a recurrent IE.
Conclusions
Patients with prior IE, a prosthetic heart valve, and complex congenital heart defect are at significantly higher associated risk of IE compared with the matched controls from the background population. These results justify the European and American guidelines in considering these groups at high risk of IE.
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